Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32931823.
- Also identified by DOI 10.1016/j.chest.2020.09.077 and PMC identifier 7486855.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.
Medical subject headings
- COVID-19
- Cytokine Release Syndrome
- Etoposide